Mapping out the future in venous thromboembolism and acute coronary syndromes

John A. Heit

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Identification of risk factors for incident venous thromboembolism and predictors of recurrent venous thromboembolism and appropriate antithrombotic prophylaxis and therapy are vital to improve survival after pulmonary embolism and prevent complications such as venous stasis syndrome after deep-vein thrombosis. Risk stratification is increasingly important; future prophylaxis and treatment strategies should be targeted to the patients who will derive the greatest benefit. For established antithrombotic agents, the most appropriate dose, dosing schedule, and duration of prophylaxis and therapy are being refined. In addition, new antithrombotic agents such as the oral direct thrombin inhibitors are being identified and developed. The management of acute arterial thrombosis (for example, acute coronary syndromes) is an important and relatively new indication for antithrombotic agents such as the low-molecular-weight heparins and the platelet glycoprotein IIb/IIIa antagonists.

Original languageEnglish (US)
Pages (from-to)33-39
Number of pages7
JournalSeminars in Thrombosis and Hemostasis
Volume28
Issue numberSUPPL. 3
StatePublished - 2002

Fingerprint

Fibrinolytic Agents
Venous Thromboembolism
Acute Coronary Syndrome
Postthrombotic Syndrome
Integrin beta3
Platelet Glycoprotein GPIIb-IIIa Complex
Antithrombins
Low Molecular Weight Heparin
Pulmonary Embolism
Venous Thrombosis
Appointments and Schedules
Thrombosis
Therapeutics
Survival

Keywords

  • Acute coronary syndromes
  • Antithrombotic agents
  • Low-molecular-weight heparin
  • Thromboprophylaxis
  • Venous thromboembolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Mapping out the future in venous thromboembolism and acute coronary syndromes. / Heit, John A.

In: Seminars in Thrombosis and Hemostasis, Vol. 28, No. SUPPL. 3, 2002, p. 33-39.

Research output: Contribution to journalArticle

@article{7d46fc92c3d5422a817fbf95aeece656,
title = "Mapping out the future in venous thromboembolism and acute coronary syndromes",
abstract = "Identification of risk factors for incident venous thromboembolism and predictors of recurrent venous thromboembolism and appropriate antithrombotic prophylaxis and therapy are vital to improve survival after pulmonary embolism and prevent complications such as venous stasis syndrome after deep-vein thrombosis. Risk stratification is increasingly important; future prophylaxis and treatment strategies should be targeted to the patients who will derive the greatest benefit. For established antithrombotic agents, the most appropriate dose, dosing schedule, and duration of prophylaxis and therapy are being refined. In addition, new antithrombotic agents such as the oral direct thrombin inhibitors are being identified and developed. The management of acute arterial thrombosis (for example, acute coronary syndromes) is an important and relatively new indication for antithrombotic agents such as the low-molecular-weight heparins and the platelet glycoprotein IIb/IIIa antagonists.",
keywords = "Acute coronary syndromes, Antithrombotic agents, Low-molecular-weight heparin, Thromboprophylaxis, Venous thromboembolism",
author = "Heit, {John A.}",
year = "2002",
language = "English (US)",
volume = "28",
pages = "33--39",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Mapping out the future in venous thromboembolism and acute coronary syndromes

AU - Heit, John A.

PY - 2002

Y1 - 2002

N2 - Identification of risk factors for incident venous thromboembolism and predictors of recurrent venous thromboembolism and appropriate antithrombotic prophylaxis and therapy are vital to improve survival after pulmonary embolism and prevent complications such as venous stasis syndrome after deep-vein thrombosis. Risk stratification is increasingly important; future prophylaxis and treatment strategies should be targeted to the patients who will derive the greatest benefit. For established antithrombotic agents, the most appropriate dose, dosing schedule, and duration of prophylaxis and therapy are being refined. In addition, new antithrombotic agents such as the oral direct thrombin inhibitors are being identified and developed. The management of acute arterial thrombosis (for example, acute coronary syndromes) is an important and relatively new indication for antithrombotic agents such as the low-molecular-weight heparins and the platelet glycoprotein IIb/IIIa antagonists.

AB - Identification of risk factors for incident venous thromboembolism and predictors of recurrent venous thromboembolism and appropriate antithrombotic prophylaxis and therapy are vital to improve survival after pulmonary embolism and prevent complications such as venous stasis syndrome after deep-vein thrombosis. Risk stratification is increasingly important; future prophylaxis and treatment strategies should be targeted to the patients who will derive the greatest benefit. For established antithrombotic agents, the most appropriate dose, dosing schedule, and duration of prophylaxis and therapy are being refined. In addition, new antithrombotic agents such as the oral direct thrombin inhibitors are being identified and developed. The management of acute arterial thrombosis (for example, acute coronary syndromes) is an important and relatively new indication for antithrombotic agents such as the low-molecular-weight heparins and the platelet glycoprotein IIb/IIIa antagonists.

KW - Acute coronary syndromes

KW - Antithrombotic agents

KW - Low-molecular-weight heparin

KW - Thromboprophylaxis

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=0036351192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036351192&partnerID=8YFLogxK

M3 - Article

C2 - 12232821

AN - SCOPUS:0036351192

VL - 28

SP - 33

EP - 39

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - SUPPL. 3

ER -